Robert J. Mullin

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan et al. · Cancer Research · 2006 · 909 citations

Medicine, Oncology, Pharmacology +11

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

Medicine, Oncology, Pharmacology +17

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 669 citations

Medicine, Oncology, Pharmacology +16

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Rakesh Kumar, Victoria B. Knick, Sharon K. Rudolph et al. · Molecular Cancer Therapeutics · 2007 · 517 citations

Medicine, Pharmacokinetics, Pharmacology +17

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Medicine, Oncology, Pharmacology +15